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Abstract
Background: Gallbladder carcinoma with peritoneal metastasis has a poor prognosis, with a median survival time
of 4.8 months. We report the survival of a patient with gallbladder carcinoma with peritoneal metastasis for 7.6
months owing to treatment with tumor resection after chemoradiotherapy.
Case presentation: A 69-year-old man was referred to our hospital for gallbladder carcinoma with hepatic
invasion. Cholecystectomy was performed along with S4a and S5 hepatectomy and extrahepatic bile duct
resection with lymph node dissection. The postoperative pathological diagnosis was moderately differentiated
adenocarcinoma, T3, N0, M0, stage IIIA by the International Union Against Cancer TNM classification. Despite
treatment with gemcitabine, the common hepatic artery and para-aortic lymph nodes showed metastases after
3 months from surgery. Although a combination of cisplatin, gemcitabine, and radiotherapy reduced the size
of the lymph node metastasis, the peritoneal metastasis persisted. The peritoneal metastasis responded to
chemoradiotherapy using tegafur-uracil and leucovorin, but it recurred. The metastasis was resected after 3 years
and 9 months from the first surgery, and chemotherapy was discontinued. Seven years and 6 months after the
initial surgery, the patient exhibited no signs of tumor recurrence or metastasis.
Conclusions: Multidisciplinary treatment including resection without residual tumors could achieve complete
remission of gallbladder carcinoma with lymph node and peritoneal metastases in the selected patient.
Keywords: Gallbladder carcinoma, Peritoneal metastasis, Long-term survival, Multidisciplinary treatment, Resection,
Chemoradiotherapy
Background
Gallbladder carcinoma (GBC) is a fatal disease with a
poor prognosis, owing to the tendency of the tumor to
metastasize early to the regional lymph nodes and
spread into the liver bed [1]. GBC with peritoneal metas-
tasis has an exceptionally poor prognosis, with a median
survival time (MST) of 4.8 months [2].
Prognostic factors for GBC invasion include liver me-
tastasis, perineural invasion [3], lymphatic invasion, and
lymph node metastasis [4]. Factors associated with sur-
vival after GBC resection include lymph node dissection
[5] with extrahepatic bile duct resection [6] and resec-
tion of the hepatic bed [7] as well as S4a and S5 hepatec-
tomy [8]. According to these reports, there is no doubt
that resection without residual tumors and lymph node
dissection or hepatic resection are important for achiev-
ing complete remission.
However, GBC with distant metastases to the liver, the
lymph nodes beyond the hepatoduodenal ligament, and
the peritoneum are typically thought to be contraindica-
tions for surgery and are treated best by chemotherapy
and radiotherapy, although the MST of patients with
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such disease is less than 1 year [2]. We report the sur-
vival of a patient with GBC with lymph node and peri-
toneal metastasis for 7.6 months; this was achieved by
controlling disease progression with chemoradiotherapy
and resection of the peritoneal metastasis.
Case presentation
A 69-year-old man was diagnosed with GBC with hep-
atic invasion after a 2-year follow-up for right breast
cancer surgery, during which his serum carcinoembryo-
nic antigen (CEA) level was elevated. He was referred to
our hospital in Jun. 2007.
Preoperatively, abdominal ultrasonography and com-
puted tomography (CT) scan revealed a tumor (37 ×
30 mm in diameter), involving the liver bed from the neck
of the gallbladder (Fig. 1). Endoscopic ultrasonography did
not reveal any cystic duct invasion; however, metastasis to
the lymph node near the common bile duct was suspected
on CT scan. Distant metastasis, including to the liver, was
not observed. The results of a blood test on admission in-
dicated that liver and kidney functions were normal. The
levels of tumor markers were as follows: CEA, 10.3 ng/mL
and carbohydrate antigen (CA) 19-9, 785.24 U/mL.
Cholecystectomy with hepatectomy of S4a and S5,
lymph node dissection of the hepatoduodenal ligament,
resection of the extrahepatic bile duct, and Roux-en-Y
choledochojejunostomy were performed in Jul. 2007. R0
resection was accomplished. The postoperative course
was uneventful.
According to the seventh edition of the Tumor Nodes
and Metastasis (TNM) Classification of the International
Union Against Cancer, the postoperative pathological
diagnosis was moderately differentiated adenocarcinoma
of the gallbladder, T3, N0, M0, stage IIIA (Fig. 2).
The patient’s clinical course and associated changes in
tumor markers are illustrated in Fig. 3. Adjuvant chemother-
apy was administered (gemcitabine [GEM], 1000 mg/m2, bi-
weekly). After 8 cycles of chemotherapy, the patient’s
CA 19-9 level had increased to 210.51 U/mL and metasta-
ses to the common hepatic artery lymph nodes and para-
aortic lymph nodes were detected in Oct. 2007 (3 months
post-surgery) on CT scan. Therefore, the chemotherapy
regimen was changed to GEM (1000 mg/m2, days 1 and
8) and TS-1 (a combination capsules of tegafur, gimeracil,
and oteracil potassium, 60 mg/m2, daily, 2 weeks on/
1 week off). GEM and TS-1 were discontinued when the
patient developed thrombopenia accompanied by eleva-
tion of CA 19-9 to 801 U/mL in Jan. 2008. A CT scan re-
vealed that the common hepatic artery lymph node
and para-aortic lymph node metastases had increased
in size by surrounding the common and proper hep-
atic arteries; the metastases reached the portal vein
bifurcation (Fig. 4).
In Mar. 2008 (8 months post-surgery), a CT scan re-
vealed an enlargement of the lymph node metastasis
with invasion into the portal vein, celiac artery, superior
mesenteric artery, duodenum, pancreas, and inferior
vena cava. A combination of low-dose cisplatin (CDDP,
6 mg/body, daily) and X-ray radiation consisting of
50 Gy/25 fr was administered. After chemotherapy and
radiation were completed in Jun. 2008 (11 months post-
surgery), CA 19-9 levels had decreased to 22.53 U/mL.
After the decrease in CA 19-9 levels, GEM (1000 mg/m2)
and CDDP (15 mg/m2) were re-administered on days 1
and 8 (2 weeks on/1 week off ). CA 19-9 decreased to
normal levels after three courses of treatment. GEM
and CDDP were continued, and stable disease was
Fig. 1 An ultrasonography image (a) and a sagittal section of a
computed tomography scan (b) showing the gallbladder carcinoma.
The red arrows indicate the tumor mass at the neck of the gallbladder,
37 × 30 mm in diameter, involving the liver bed
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maintained according to the Response Evaluation Cri-
teria in Solid Tumor (RECIST). In Dec. 2009 (2 years
and 5 months post-surgery), after 28 courses of treat-
ment had been administered in total, a new metastatic
lesion was detected near the colon of the hepatic flex-
ure on a CT scan and was diagnosed as a peritoneal
metastasis.
Owing to the discovery of the additional metastasis, the
chemotherapy regimen was changed to uracil and tegafur
(UFT, 300 mg/body) and leucovorin (25 mg/body), which
were administered daily (4 weeks on/1 week off), in Jan.
2010 (2 years and 6 months post-surgery). X-ray radiation
of 40 Gy/20 fr was also administered. After treatment, the
levels of tumor markers decreased to normal, and a CT
scan revealed reduced tumor size of the peritoneal metas-
tasis (Fig. 5).
In Apr. 2011 (3 years and 9 months post-surgery),
after 16 courses of UFT and leucovorin treatment, the
levels of tumor markers had once again increased and
the size of the peritoneal metastasis had increased.
Radiotherapy treatment was no longer possible because
the patient had reached the maximum dose allowable
and because of the risk for adverse gastrointestinal ef-
fects. Multiple imaging modalities including CT, mag-
netic resonance imaging (MRI), and positron emission
tomography (PET/CT) revealed that the peritoneal me-
tastasis was isolated. Also, the lymph node metastases of
hepatoduodenal ligament and para-aorta maintained
stable disease and did not show any viability. Therefore,
the peritoneal metastasis was resected in Apr. 2011.
Open laparotomy findings did not reveal any peritoneal
dissemination except the isolated peritoneal metastasis.
The metastatic mass was 18 × 15 mm in size and was
resected without a residual tumor. The postoperative
pathological diagnosis was a metastatic adenocarcinoma.
The effect of radiotherapy was also observed, and its ef-
fect was evaluated as grade 1b (about half of tumor cells
showed highly change).
After resection, chemotherapy was discontinued be-
cause the tumor marker levels were within normal
limits. PET/CT scan obtained in Nov. 2011 did not re-
veal any tumors.
At the time of reporting, 7.6 months have passed since
the primary tumor was removed, and 3 years and 9 months
have passed since the peritoneal metastasis was resected.
At this time, the levels of tumor markers are within nor-
mal limits and tumor recurrences have not been detected
on CT scan.
Discussion
In this report, we demonstrate a rare case of long-term
disease-free survival in a patient with recurrent GBC
with lymph node and peritoneal metastases by using
multidisciplinary treatments including resection, chemo-
therapy, and radiotherapy.
The poor prognosis of advanced GBC, such as that with
distant metastasis to the liver, peritoneum, or lymph nodes
of the extrahepatoduodenal ligament or para-aorta, is well
recognized. Because of the difficulty associated with
complete resection, chemotherapy or radiotherapy is usu-
ally utilized in these advanced GBC cases [9]. The main
chemotherapeutic agents for GBC include GEM, CDDP,
and 5-fluorouracil, alone or in combination. According to
a phase II study, 1000 mg/m2 of GEM elicited a 17.5 % re-
sponse rate (RR) with an MST of 7.6 months in cases of
advanced GBC [10]. TS-1 elicited a 35 % RR with an MST
of 9.4 months [11]. The combination of GEM and CDDP
elicited a 21 to 48 % RR with an MST of 4.6 to
11.0 months in several reports [12–15]. Although these
were cohort studies, randomized trials evaluating the ef-
fect of these drugs alone and with other agents, such as
epirubicin, etoposide, leucovorin, mitomycin C, and cape-
citabine, have been performed but have not demonstrated
positive outcomes [16–18]. Adjuvant chemotherapy has
also been thought to play a marginal role in the treatment
of GBC.
Thus, resection without residual tumors, if possible,
still has an important role in improving the prognosis of
advanced GBC. Several previous reports support the no-
tion that radical resection of advanced GBC enhances
survival [19–21]. Watanabe et al. reported the survival
of a patient with advanced GBC for more than 12 years
after curative surgery that included cholecystectomy,
liver bed resection, pancreatoduodenectomy, right hemi-
colectomy, and anterior abdominal wall resection [22].
Fig. 2 The cut surface of the resected specimen. The red arrow
indicates the tumor mass at the neck of the gallbladder involving
the liver bed, which was pathologically diagnosed as a moderately
differentiated adenocarcinoma. The lymph node, cystic duct, cystic
artery, and other surrounding organs were negative for invasion.
Hepatic metastasis was not observed. The gallbladder was injected
with indocyanine green, which was used to observe the cystic vein
perfusion area
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Even in cases of metastatic GBC, if the metastatic le-
sions were surgically resectable and well controlled with
chemotherapy and/or radiotherapy, resection with nega-
tive margins might result in long-term survival and
complete remission. A previous report showed that pa-
tients with advanced GBC could benefit from resection
even when para-aortic lymph node metastasis and/or
liver metastasis are present [2]. Scaringi et al. reported a
patient with recurrent GBC who was treated with itera-
tive resection and was alive and disease-free 5 years after
the final surgical procedure [23]. In their case, fluorouracil
and leucovorin were administered as adjuvant chemother-
apy; however, splenic metastasis appeared after 1 year
from the first operation. Even though the splenic metasta-
sis was resected, pancreatic and gastric metastases ap-
peared after another year. Distal pancreatectomy en bloc
with sleeve gastrectomy was performed, and the patient
was alive for 5 years. Only a few reports have demon-
strated the long-term survival of patients with recurrent
GBC treated with resection of metastatic lesions, similar
to our case.
Our current case demonstrated that long-term survival
could be achieved with resection of metastatic lesions of
GBC, if the metastatic lesion was isolated, resectable,
and well controlled with chemoradiotherapy. The cri-
teria to confirm the isolation of metastasis and the defin-
ition of “well controlled” are controversial, and multiple
imaging modalities including CT, MRI, and PET/CT
could be helpful to confirm it. Also, the definition of re-
sectability is different between surgeons or institutions,
and further investigations are needed to provide consist-
ent evidence.
Conclusions
In conclusion, despite significant developments in the
fields of chemotherapy and/or radiotherapy, resection
without residual tumor might have an important role in
improving the prognosis of recurrent GBC. Resection
should be considered if the metastatic lesion is isolated
and well controlled with chemoradiotherapy in order to
achieve complete remission and/or long-term survival.
Fig. 3 Clinical course and tumor marker levels. The blue line illustrates the level of carcinoembryonic antigen (CEA), and the pink line illustrates the
level of carbohydrate antigen (CA) 19-9. Abbreviations: GEM gemcitabine, TS-1 combination capsules of tegafur, gimeracil, and oteracil potassium,
CDDP cisplatin, RTx radiotherapy, UFT uracil and tegafur, LV leucovorin, LNs lymph nodes
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Fig. 4 Progression of the metastasis to the common hepatic artery and para-aortic lymph nodes. The lymph node metastasis was detected
3 months after the first resection (a). Despite administration of gemcitabine (GEM) plus TS-1 and cisplatin (CDDP) plus radiation, the metastasis
enlarged and involved the portal vein (b). However, the growth rate remarkably decreased after GEM plus CDDP (c) and uracil and tegafur plus
leucovorin (d) administration and has maintained the same size
Fig. 5 Change in peritoneal metastasis near the hepatic flexure. Peritoneal metastasis was detected 2 years after the first resection (a). It decreased
in size after treatment with gemcitabine plus cisplatin and uracil and tegafur (UFT) plus leucovorin (LV) with radiation (b). However, the peritoneal
metastasis began to enlarge during UFT plus LV administration (c) and was resected in a second surgery in Apr. 2011 (d)
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